AU9052991A - Use of angiotensin ii antagonist in the treatment of infarction - Google Patents

Use of angiotensin ii antagonist in the treatment of infarction

Info

Publication number
AU9052991A
AU9052991A AU90529/91A AU9052991A AU9052991A AU 9052991 A AU9052991 A AU 9052991A AU 90529/91 A AU90529/91 A AU 90529/91A AU 9052991 A AU9052991 A AU 9052991A AU 9052991 A AU9052991 A AU 9052991A
Authority
AU
Australia
Prior art keywords
angiotensin
infarction
antagonist
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU90529/91A
Inventor
James Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of AU9052991A publication Critical patent/AU9052991A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU90529/91A 1990-12-14 1991-12-12 Use of angiotensin ii antagonist in the treatment of infarction Abandoned AU9052991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB909027208A GB9027208D0 (en) 1990-12-14 1990-12-14 Medicaments
GB9027208 1990-12-14

Publications (1)

Publication Number Publication Date
AU9052991A true AU9052991A (en) 1992-07-08

Family

ID=10687042

Family Applications (1)

Application Number Title Priority Date Filing Date
AU90529/91A Abandoned AU9052991A (en) 1990-12-14 1991-12-12 Use of angiotensin ii antagonist in the treatment of infarction

Country Status (5)

Country Link
EP (1) EP0561878A1 (en)
JP (1) JPH06503322A (en)
AU (1) AU9052991A (en)
GB (1) GB9027208D0 (en)
WO (1) WO1992010180A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5185351A (en) * 1989-06-14 1993-02-09 Smithkline Beecham Corporation Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists
EP0577025A3 (en) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-ii-receptorantagonist for the treatment and prophylaxis of coronary heart diseases
NZ513039A (en) * 1999-01-26 2003-11-28 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
CN101011390A (en) 1999-01-26 2007-08-08 诺瓦提斯公司 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US6552033B1 (en) 2000-05-16 2003-04-22 The Procter & Gamble Co. Imidazo-containing heterocyclic compounds, their compositions and uses
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (en) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc AGONISTS OF GUANYLATE CYCLASE USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS, INFLAMMATION, CANCER and OTHER DISORDERS.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010009319A2 (en) 2008-07-16 2010-01-21 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP6606491B2 (en) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド Ultra high purity agonist of guanylate cyclase C, method for producing and using the same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0241201A3 (en) * 1986-04-07 1990-05-23 Merck & Co. Inc. Angiotensin converting enzyme inhibitors useful in prolonging survival of mammalians with congestive heart failure
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists
CA2018443A1 (en) * 1989-06-14 1990-12-14 Joseph A. Finkelstein Imidazolyl-alkenoic acids
SG52330A1 (en) * 1989-06-14 1998-09-28 Smithkline Beecham Corp Imidazolyl-alkenoic acids
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof

Also Published As

Publication number Publication date
JPH06503322A (en) 1994-04-14
EP0561878A1 (en) 1993-09-29
WO1992010180A1 (en) 1992-06-25
GB9027208D0 (en) 1991-02-06

Similar Documents

Publication Publication Date Title
IL115717A0 (en) Heterocyclic compounds and their preparation and use
AU7122291A (en) 3-arylcarbonyl-1h-indoles useful as therapeutic agents
EP0788489A4 (en) Heterocyclic compounds and their use
AU3959193A (en) Heterocyclic compounds and their use in the treatment of type II-diabetes
AU9058591A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic nephropathy
AU9064991A (en) Use of angiotensin ii receptor antagonists in the treatment of diabetic retinopathy
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
ZA927172B (en) Heterocyclic compounds and their preparation and use.
ZA941926B (en) Heterocyclic compounds their preparation and use
ZA929770B (en) Heterocyclic compounds and their preparation and use
AU9069191A (en) Use of angiotensin ii receptor antagonists in the prevention of restinosis
AU3745895A (en) Use of gaba antagonists in the treatment of emesis
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
AU9065291A (en) Use of angiotensin ii receptor antagonists in the treatment of macular degeneration
AU9081691A (en) Use of angiotensin ii antagonists in the treatment of angina pectoris
AU9064191A (en) Use of angiotensin ii receptor antagonists in the treatment of atheroma
AU9071291A (en) Use of angiotensin ii antagonists in the treatment of left ventricular hypertrophy
AU4585993A (en) Use of angiotensin ii antagonists for the treatment of hyperlipidaeme
AU4812393A (en) Use of rapamycin in the treatment of aids
EP0440559A3 (en) Polyolefin composition and use thereof
ZA969586B (en) The use of cholinesterase inhibitors in the treatment of xerostomia
IL114490A0 (en) Heterocyclic compounds their preparation and their use
GB2274823B (en) Medical dressing aid pack
AU7730991A (en) Halopropargyl compounds and the use thereof as microbicides
ZA928198B (en) Substituted azaspiranes for use in the treatment of hyperlipidemia